c‐Jun N‐terminal Kinase mediates prostaglandin‐induced sympathoexcitation in rats with chronic heart failure by reducing <scp>GAD</scp>1 and <scp>GABRA</scp>1 expression

Wang, Renjun; Zhang, Wen; Dong, Zengxiang; Qi, Yunfeng; Hultström, Michael; Zhou, Xiaofu; Lai, En Yin

doi:10.1111/apha.12758

Cited by 4 publications

(2 citation statements)

References 42 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The non-selective EP receptor antagonist AH6809 has been widely applied to explore the roles of PGE2/EP2 signaling under normal and pathological conditions (109). Although AH6809 acts as an antagonist of EP2, it may also serve as an antagonist of EP1 and dP1 (110); it is neither selective nor potent, and is therefore unsuitable for in vivo studies (111).…”

Section: Development Of Agonists Antagonists and Targeted Drugs For Ep2mentioning

confidence: 99%

Prostaglandin EP2 receptor: Novel therapeutic target for human cancers (Review)

Sun

2018

Int J Mol Med

View full text Add to dashboard Cite

Prostaglandin E2 (PGE2) receptor 2 subtype (EP2), which is a metabolite of arachidonic acid that binds with and regulates cellular responses to PGE2, is associated with numerous physiological and pathological events in a wide range of tissues. As a stimulatory G protein‑coupled receptor, PGE2‑induced EP2 activation can activate adenylate cyclase, leading to increased cytoplasmic cAMP levels and activation of protein kinase A. The EP2 receptor can also activate the glycogen synthase kinase 3β and β‑catenin pathways. The present study aimed to review the roles of the EP2 receptor in tumor development, including immunity, chronic inflammation, angiogenesis, metastasis and multidrug resistance. Furthermore, the involvement of the EP2 receptor signaling pathway in cancer was discussed. Understanding the role and mechanisms of action of the EP2 receptor, and its importance in targeted therapy, may help identify novel methods to improve management of numerous types of cancer.

show abstract

Section: Development Of Agonists Antagonists and Targeted Drugs For Ep2mentioning

confidence: 99%

Prostaglandin EP2 receptor: Novel therapeutic target for human cancers (Review)

Sun

2018

Int J Mol Med

View full text Add to dashboard Cite

show abstract

“…The mechanisms causing the increase in renal sympathetic nerve activity remain to be elucidated. Wang et al have recently described how c‐Jun N‐terminal Kinase reduces GAD1 and GABRA1 expression, thereby mediating prostaglandin‐induced sympatho‐excitation in a rat model of chronic heart failure. Lu et al describe that renal denervation benefits cardiac angiogenesis during sustained pressure overload by a regulation of VEGF and VEGFR2 expression and eNOS activation.…”

Section: Contractile Function and Heart Failurementioning

confidence: 99%